scholarly journals Atherogenic index of plasma is an independent predictor of ultrasound-proven nonalcoholic fatty liver disease among non-obese populations.

2021 ◽  
Author(s):  
Hua-Jun Ye ◽  
Xu-Yan Chen ◽  
Zhi-Ming Huang ◽  
XiXi He
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Independent Predictor ◽  
Tertiary Hospital ◽  
Atherogenic Index ◽  
Alcoholic Fatty Liver ◽  
Atherogenic Index Of Plasma ◽  
Nonalcoholic Fatty Liver

Abstract Background & Aims: Evidence regarding the association between atherogenic index of plasma (AIP) and the risk of non-alcoholic fatty liver disease (NAFLD) in non-obese populations is limited. Our study aimed to investigate whether AIP predicts NAFLD in non-obese Chinese populations.Methods: The present study was a population-based longitudinal study, including 16 173 non-obese participants who underwent health examinations in a tertiary hospital from January 2010 to December 2014. The primary outcome was developing NAFLD during the follow-up period. Results: The mean age of the included participants was 43.2 ± 15.0 years old, and about 52.5% of them were male. During the follow-up period, 2 322 of 16 173 (14.3%) participants developed NAFLD. In the fully-adjusted model, for every one standard deviation increased in AIP levels, the incidence of NAFLD increased by 52% (1.52, 95%CI 1.43, 1.60). The optimal cut-off point of AIP for incident NAFLD was 0.00 (receiver operator characteristic 0.76 [95% CI 0.75–0.77], sensitivity 0.68, specificity 0.72). Individuals with AIP values in the positive range had two-fold increased odds of developing NALFD compared with those with values in the negative range. After propensity score matching, for every one-SD increased in AIP levels, the incidence of NAFLD increased by 34% (HR 1.34, 95%CI 1.27, 1.41). Conclusion: AIP is an independent predictor of incident NAFLD among Chinese non-obese populations.

scholarly journals Atherogenic index of plasma is an independent predictor of ultrasound-proven nonalcoholic fatty liver disease among non-obese populations

2021 ◽  
Author(s):  
Hua-Jun Ye ◽  
Xu-Yan Chen ◽  
XiXi He
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Independent Predictor ◽  
Density Lipoprotein ◽  
Atherogenic Index ◽  
Alcoholic Fatty Liver ◽  
Atherogenic Index Of Plasma ◽  
Nonalcoholic Fatty Liver

Abstract Background & AimsEvidence regarding the association between atherogenic index of plasma (AIP) and the risk of non-alcoholic fatty liver disease (NAFLD) in non-obese populations is limited. Our study aimed to investigate whether AIP predicts NAFLD in non-obese Chinese populations.MethodsThe present study was a population-based longitudinal study, including 16 173 non-obese participants who underwent health examinations in a tertiary hospital from January 2010 to December 2014. The primary outcome was developing NAFLD during the follow-up period. AIP was calculated as Log (Triglycerides/ high-density lipoprotein cholesterol).ResultsThe mean age of the included participants was 43.2 ± 15.0 years old, and about 52.5% of them were male. During the follow-up period, 2 322 of 16 173 (14.3%) participants developed NAFLD. In the fully-adjusted model, for every one standard deviation increased in AIP levels, the incidence of NAFLD increased by 52% (1.52, 95%CI 1.43, 1.60). The optimal cut-off point of AIP for incident NAFLD was 0.00 (receiver operator characteristic 0.76 [95% CI 0.75–0.77], sensitivity 0.68, specificity 0.72). Individuals with AIP values in the positive range had two-fold increased odds of developing NALFD compared with those with values in the negative range. After propensity score matching, for every one-SD increased in AIP levels, the incidence of NAFLD increased by 34% (HR 1.34, 95%CI 1.27, 1.41).ConclusionAIP is an independent predictor of incident NAFLD among Chinese non-obese populations.

scholarly journals The value of the atherogenic index of plasma in non-obese people with non-alcoholic fatty liver disease: a secondary analysis based on a cross-sectional study

2020 ◽  
Author(s):  
Buyuan Dong ◽  
Yuqing Mao ◽  
Zhengyang Li ◽  
Fujun Yu
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Operating Characteristic ◽  
Characteristic Curve ◽  
Atherogenic Index ◽  
Obese People ◽  
Alcoholic Fatty Liver ◽  
Atherogenic Index Of Plasma ◽  
Alcoholic Fatty Liver Disease

Abstract Background and objectives: The atherogenic index of plasma (AIP) is elevated in fatty liver disease, but its value in non-obese people with non-alcoholic fatty liver disease (NAFLD) is unclear. This study aimed to investigate the relationship between AIP and NAFLD as well as to determine whether AIP might be used as an indicator of NAFLD in non-obese individuals. Methods : The present study involved non-obese Chinese and Japanese participants. Univariate and multivariate logistic regression models were used to determine risk factors. The performance of risk factors was compared according to the area under the receiver operating characteristic curve. Results : In the unadjusted model, the odds ratio (OR) for every 1 standard deviation (SD) increase in AIP was 52.30. In adjusted models I and II, the OR for every 1 SD increase in AIP was 36.57 and 50.84, respectively. The area under the receiver operating characteristic curve for AIP was 0.803 and 0.802 in the development and validation groups, respectively. The best cut-off value of AIP for discrimination between NAFLD and non-NAFLD was 0.005 in the Chinese group and -0.220 in the Japanese group. Conclusions : AIP and NAFLD are positively correlated in Chinese and Japanese populations. Therefore, AIP can be used as a new screening indicator for non-obese people with NAFLD in different nations.

New therapy for fatty liver

2018 ◽  
Vol 1 (2) ◽  
pp. 24-28
Author(s):  
Tanita Suttichaimongkol
Keyword(s):  
Oxidative Stress ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Lifestyle Modifications ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Liver Insulin Resistance ◽  
Alcoholic Fatty Liver Disease ◽  
Related Mortality

Non-alcoholic fatty liver disease (NAFLD) is a leading cause of death from liver cirrhosis, endstage liver disease, and hepatocellular carcinoma. It is also associated with increased cardiovasculardisease and cancer related mortality. While lifestyle modifications are the mainstay of treatment,only a proportion of patients are able to make due to difficult to achieve and maintain, and so moretreatment options are required such as pharmacotherapy. This review presents the drugs used inmanaging NAFLD and their pharmacologic targets. Therapies are currently directed towards improvingthe metabolic status of the liver, insulin resistance, cell oxidative stress, apoptosis, inflammation orfibrosis. Several agents are now in large clinical trials and within the next few years, the availability oftherapeutic options for NAFLD will be approved.     Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, fibrosis, cirrhosis  

Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease

2020 ◽  
Vol 21 (6) ◽  
pp. 599-609 ◽  
Author(s):  
Longxin Qiu ◽  
Chang Guo
Keyword(s):  
Oxidative Stress ◽  
Liver Disease ◽  
Fatty Liver ◽  
Aldose Reductase ◽  
Fatty Liver Disease ◽  
Acid Oxidation ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver

Aldose reductase (AR) has been reported to be involved in the development of nonalcoholic fatty liver disease (NAFLD). Hepatic AR is induced under hyperglycemia condition and converts excess glucose to lipogenic fructose, which contributes in part to the accumulation of fat in the liver cells of diabetes rodents. In addition, the hyperglycemia-induced AR or nutrition-induced AR causes suppression of the transcriptional activity of peroxisome proliferator-activated receptor (PPAR) α and reduced lipolysis in the liver, which also contribute to the development of NAFLD. Moreover, AR induction in non-alcoholic steatohepatitis (NASH) may aggravate oxidative stress and the expression of inflammatory cytokines in the liver. Here, we summarize the knowledge on AR inhibitors of plant origin and review the effect of some plant-derived AR inhibitors on NAFLD/NASH in rodents. Natural AR inhibitors may improve NAFLD at least in part through attenuating oxidative stress and inflammatory cytokine expression. Some of the natural AR inhibitors have been reported to attenuate hepatic steatosis through the regulation of PPARα-mediated fatty acid oxidation. In this review, we propose that the natural AR inhibitors are potential therapeutic agents for NAFLD.

scholarly journals Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Andrew Yang ◽  
Melinda Nguyen ◽  
Irene Ju ◽  
Anthony Brancatisano ◽  
Brendan Ryan ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Weight Loss ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Stiffness ◽  
Convincing Evidence ◽  
Alcoholic Fatty Liver ◽  
Post Surgery

AbstractSignificant weight loss can modify the progression of Nonalcoholic fatty liver disease (NAFLD) with the most convincing evidence coming from bariatric surgery cohorts. Effective ways to non-invasively characterise NAFLD in these patients has been lacking, with high Fibroscan failure rates reported. We prospectively evaluated the utility of Fibroscan using XL-probe over a two-year period. 190 consecutive patients undergoing bariatric surgery were followed as part of their routine care. All patients had Fibroscan performed on the day of surgery and at follow-up a mean of 13 months (± 6.3) later. The majority of patients were female (82%) with mean age of 42. Fibroscan was successful in 167 (88%) at baseline and 100% at follow up. Patients with a failed Fibroscan had higher body mass index (BMI) and alanine transaminase (ALT), but no difference in FIB-4/NAFLD score. Mean baseline Liver stiffness measurement was 5.1 kPa, with 87% of patients classified as no fibrosis and 4% as advanced fibrosis. Mean baseline controlled attenuation parameter was 291, with 78% having significant steatosis, 56% of which was moderate-severe. Significant fibrosis was associated with higher BMI and HbA1c. Significant steatosis was associated with higher BMI, ALT, triglycerides and insulin resistance. Mean follow up time was 12 months with weight loss of 25.7% and BMI reduction of 10.4 kg/m2. Seventy patients had repeat fibroscan with reductions in steatosis seen in 90% and fibrosis in 67%. Sixty-four percent had complete resolution of steatosis. Fibroscan can be performed reliably in bariatric cohorts and is useful at baseline and follow-up. Significant steatosis, but not fibrosis was seen in this cohort with substantial improvements post-surgery.

scholarly journals Collagen proportionate area is an independent predictor of long-term outcome in patients with non-alcoholic fatty liver disease

2019 ◽  
Vol 49 (9) ◽  
pp. 1214-1222 ◽  
Author(s):  
Elena Buzzetti ◽  
Andrew Hall ◽  
Mattias Ekstedt ◽  
Roberta Manuguerra ◽  
Marta Guerrero Misas ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Independent Predictor ◽  
Term Outcome ◽  
Alcoholic Fatty Liver ◽  
Long Term Outcome ◽  
Alcoholic Fatty Liver Disease

scholarly journals Prevalence and Predictor of Nonalcoholic Steatohepatitis (NASH) in Nonalcoholic Fatty Liver Disease (NAFLD)

2015 ◽  
Vol 32 (2) ◽  
pp. 71-77 ◽  
Author(s):  
Shahinul Alam ◽  
Mahabubul Alam ◽  
Sheikh Mohammad Noor E Alam ◽  
Ziaur Rahman Chowdhury ◽  
Jahangir Kabir
Keyword(s):  
Metabolic Syndrome ◽  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Resistance Index ◽  
Histopathological Study ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Fatty liver is a common cause of chronic liver disease in developed as well as developing countries.We have designed this study to estimate the prevalence and predictors for non alcoholic steatohepatitis (NASH) in non alcoholic fatty liver disease (NAFLD). We have included 493 patients with sonographic evidence of fatty change in liver and 177 of them had done liver biopsy for histopathological study. Other causes of liver disease and alcohol consumption were excluded. Metabolic syndrome and biochemical and anthropometric evaluation was done. Females were predominating 250 (57.0 %). Centrally obese 422 (96.2 %) was more than over all obesity330 (75.1%). NASH was absent in 10 (5.6%) cases and diagnostic of NASH was 75 Journal of Bangladesh College of Physicians and Surgeons Vol. 32, No. 2, April 2014 (42.4 %).Presence of diabetes could significantly (p = 0.001) predicted NASH. Age, sex, BMI, waist circumference, Serum HDL,triglyceride, insulin resistance index, hypertension, metabolic syndrome could not predict NASH. Serum GGT level was significantly (p = 0.05) higher in NASHwith a sensitivity of 45 % and specificity of 68 % only. Serum ALT and AST level could not detect NASH. Females were predominant sufferer of NAFLD in Bangladesh. Prevalence of NASH was much higher42.4%. Diabetes was the main predictor of NASH. GGT was the only biochemical indicator of NASH. We recommend liver biopsy in NAFLD with diabetes and raised GGT.J Bangladesh Coll Phys Surg 2014; 32: 71-77

Sign in / Sign up

Export Citation Format

Share Document